MRSN - Mersana Therapeutics Inc. (MRSN) Q1 2024 Earnings Call Transcript
2024-05-09 14:09:08 ET
Mersana Therapeutics, Inc. (MRSN)
Q1 2024 Earnings Conference Call
May 09, 2024 08:00 AM ET
Company Participants
Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications
Martin Huber - President & Chief Executive Officer
Brian DeSchuytner - Chief Financial Officer & Chief Operating Officer
Conference Call Participants
Tara Bancroft - TD Cowen
Kaveri Pohlman - BTIG
Dylan Drakes - Leerink Partners
Brian Cheng - JPMorgan
Michael Schmidt - Guggenheim
Asthika Goonewardene - Truist
Ashiq Mubarack - Citi
Colleen Kusy - Baird
Presentation
Operator
Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast. Currently, all participants are in listen-only mode. There will be a question-and-answer session, at the end of this call.
I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications. Please note, this call is being recorded.
Jason Fredette
Thank you, operator, and good morning, everyone.
Before we begin, please note that this call will contain forward-looking statements within the meaning of Federal Securities Laws. These statements may include, but are not limited to those related to our platforms, product candidates, business strategy, clinical trial execution and data, business development efforts and cash runway. Each of these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements....
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript